DekaLux-BioTech TF |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 14.1 | 6.5 | -7.9 | 0.6 | 2.4 | |
+/-Cat | -5.1 | 9.5 | 4.9 | -0.5 | -1.3 | |
+/-Idx | -11.7 | -0.4 | -4.8 | -9.3 | -7.6 | |
Category: Sector Equity Biotechnology | ||||||
Benchmarks: Morningstar Gbl Biotechnolo... |
Key Stats | ||
NAV 22/04/2024 | EUR 463.44 | |
Day Change | 0.13% | |
Morningstar Category™ | Sector Equity Biotechnology | |
ISIN | LU0348461897 | |
Fund Size (Mil) - | - | |
Share Class Size (Mil) 22/04/2024 | EUR 150.94 | |
Max Initial Charge | - | |
Ongoing Charge 19/01/2024 | 2.30% |
Investment Objective: DekaLux-BioTech TF |
N/A |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 02/06/2008 | ||
Inception Date 02/06/2008 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR EUR | Morningstar Gbl Biotechnology NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for DekaLux-BioTech TF | 31/12/2023 |
|
|
Top 5 Holdings | Sector | % |
Vertex Pharmaceuticals Inc | Healthcare | 8.88 |
Regeneron Pharmaceuticals Inc | Healthcare | 7.17 |
Amgen Inc | Healthcare | 6.96 |
Gilead Sciences Inc | Healthcare | 6.60 |
Alnylam Pharmaceuticals Inc | Healthcare | 3.08 |
Increase Decrease New since last portfolio | ||
DekaLux-BioTech TF |